Drug Pricing Models

In the wake of numerous articles on the high cost of new drugs, several organizations have developed drug pricing models. With a number of these scorecards arriving at the same time to raise the profile of cost versus value, could they pose a major threat to pharma? Jeff Waldron, of Diaceutics' PM Connective, examines three recent models and attempts to find out.|In the wake of numerous articles on the high cost of new drugs, several organizations have developed drug pricing models. With a number of these scorecards arriving at the same time to raise the profile of cost versus value, could they pose a major threat to pharma? Jeff Waldron, of Diaceutics' PM Connective, examines three recent models and attempts to find out.|In the wake of numerous articles on the high cost of new drugs, several organizations have developed drug pricing models. With a number of these scorecards arriving at the same time to raise the profile of cost versus value, could they pose a major threat to pharma? Jeff Waldron, of Diaceutics' PM Connective, examines three recent models and attempts to find out.|In the wake of numerous articles on the high cost of new drugs, several organizations have developed drug pricing models. With a number of these scorecards arriving at the same time to raise the profile of cost versus value, could they pose a major threat to pharma? Jeff Waldron, of Diaceutics' PM Connective, examines three recent models and attempts to find out.